SCHEDULE 13G/A: Wellington Management Group Discloses 9.5% Beneficial Ownership in Amicus Therapeutics

Wellington Management Group LLP and its affiliates have reported a 9.5% beneficial ownership stake in Amicus Therapeutics, Inc. as of December 31, 2024.

Summary

• Wellington Management Group LLP, along with its affiliated entities Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP, collectively hold a 9.5% beneficial ownership stake in Amicus Therapeutics, Inc.
• This significant stake amounts to 28,461,994 shares of Amicus Therapeutics' Common Stock.
• The reporting persons possess shared voting power over 27,400,307 shares and shared dispositive power over all 28,461,994 shares.
• This filing is an Amendment No. 2 to a Schedule 13G, indicating an update to a previously reported passive investment position.
• The securities are held on behalf of clients of Wellington's various investment advisers, with no single client (other than Vanguard Health Care Fund) individually known to hold more than 5% of the class.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive stake by a reputable institutional investor like Wellington Management Group is generally viewed positively by the market, as it signals confidence in the company. However, the document itself is purely factual and does not contain forward-looking statements or operational details that would significantly sway sentiment beyond the fact of the investment.

Positives

• The disclosure of a substantial 9.5% stake by a major institutional investor like Wellington Management Group signals significant institutional confidence in Amicus Therapeutics.
• The filing is a routine passive investment disclosure, indicating no intent to influence or control the issuer, which can be viewed as a stable, long-term holding.

Future Outlook

NA

Industry Context

This filing indicates a significant passive investment by a major asset manager in Amicus Therapeutics, a biotechnology company. Such large institutional holdings are common in the biotech sector, reflecting investor interest in companies with promising pipelines or market positions.

Stakeholder Impact

• The significant stake held by Wellington Management Group LLP and its affiliates may reassure existing shareholders by demonstrating institutional confidence in Amicus Therapeutics.
• This filing primarily impacts shareholders by providing transparency on major ownership stakes.

Key Dates

Keywords

Amicus Therapeutics, Wellington Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Biotechnology, Pharmaceuticals